Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317375 | 1.00 | LMNA (0.68) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL9576503 | 1.00 | LMNA (0.68) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL6724069 | 1.00 | LMNA (0.68) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL9576491 | 0.98 | LMNA (0.70) | LMNANAAAFAAHL3MBTL1MEN1 | |
| Bicarbonate SCHEMBL5682661 | 0.97 | LMNA (0.64) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL31632703 | 0.95 | LMNA (0.61) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL4331647 | 0.95 | LMNA (0.61) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL9576439 | 0.95 | LMNA (0.61) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL6863387 | 0.95 | LMNA (0.61) | LMNANAAAFAAHL3MBTL1MEN1 | |
| SCHEMBL8378836 | 0.95 | LMNA (0.61) | LMNANAAAFAAHL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539259-B2 | Hygiene product pod and methods of using same | CMC Group, Inc. (US) | 2026-02-03 | — | — | US | claimed |
| EP-4134407-A1 | TWO-COMPONENT INK FOR SKIN PRINT AND PRINTING METHOD FOR TWO-COMPONENT INK FOR SKIN PRINT | Prinker Korea Inc. (KR) | 2023-02-15 | — | — | EP | claimed |
| US-20230000728-A1 | Hygiene Product Pod and Methods of Using Same | CMC Group, Inc. | 2023-01-05 | — | — | US | claimed |
| EP-4054515-A1 | HYGIENE PRODUCT POD AND METHODS OF USING SAME | Nohbo, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| CN-113797180-A | Percutaneous absorption preparation containing donepezil as active ingredient | Icure药品株式会社 | 2021-12-17 | — | — | CN | claimed |
| US-10888533-B2 | Transdermal composition containing donepezil as active ingredient | ICURE PHARMACEUTICAL INC. (KR) | 2021-01-12 | — | — | US | claimed |
| EP-3342846-B1 | SELF-DISSOLUBLE CAPSULE FOR PREPARATION OF WASHING SOLUTIONS | GRUPA INCO S A (PL) | 2020-04-08 | — | — | EP | claimed |
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2019-03-28 | — | — | US | claimed |
| EP-3235494-A1 | TRANSDERMAL PREPARATION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | Icure Pharmaceutical Inc. (KR) | 2017-10-25 | — | — | EP | claimed |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | ICURE PHARMACEUTICAL INC. (KR) | 2017-10-12 | — | — | US | claimed |
| CN-102946873-B | percutaneous absorption preparation | ICURE PHARM INC | 2015-05-13 | — | — | CN | claimed |
| CN-103930098-A | Transdermal preparation containing fentanyl and its congener | TRANSDERM INC | 2014-07-16 | — | — | CN | claimed |
| CN-102946873-A | Percutaneous absorption preparation | ICURE PHARM INC | 2013-02-27 | — | — | CN | claimed |
| US-12629327-B2 | Keratin-based hair straightening formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-5034386-A | Fungicides | WHITBY RESEARCH, INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4886783-A | Penetration enhancers for transdermal delivery of systemic agents | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-12-12 | — | — | US | disclosed |
| US-4886545-A | IMPROVE DELIVERY OF PLANT NUTRIENTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0268218-A2 | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, Inc. (US) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539259-B2 | Hygiene product pod and methods of using same | DAGLA, ABHD12, CUTA | LMNA 4099/4885NAAA 1856/4885FAAH 22/4885 |
| US-12629327-B2 | Keratin-based hair straightening formulations, methods and systems | KRT18, HCN4, COL14A1 | LMNA 915/4885NAAA 2256/4885FAAH 3621/4885 |
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | APP, PSEN2, PSEN1 | LMNA 2890/4885NAAA 632/4885FAAH 290/4885 |
| US-10888533-B2 | Transdermal composition containing donepezil as active ingredient | PSEN1, ACHE, CUTA | LMNA 3229/4885NAAA 690/4885FAAH 912/4885 |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | PSEN1, ACHE, CUTA | LMNA 3229/4885NAAA 690/4885FAAH 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.